Division of Clinical Decision Making, Tufts Medical Center, School of Medicine, Tufts University, Boston, Massachusetts 02111, USA.
Nutr Rev. 2011 Sep;69(9):533-49. doi: 10.1111/j.1753-4887.2011.00412.x.
Increased interest in the potential societal benefit of incorporating health economics as a part of clinical translational science, particularly nutrition interventions, led the Office of Dietary Supplements at the National Institutes of Health to sponsor a conference to address key questions about the economic analysis of nutrition interventions to enhance communication among health economic methodologists, researchers, reimbursement policy makers, and regulators. Issues discussed included the state of the science, such as what health economic methods are currently used to judge the burden of illness, interventions, or healthcare policies, and what new research methodologies are available or needed to address knowledge and methodological gaps or barriers. Research applications included existing evidence-based health economic research activities in nutrition that are ongoing or planned at federal agencies. International and US regulatory, policy, and clinical practice perspectives included a discussion of how research results can help regulators and policy makers within government make nutrition policy decisions, and how economics affects clinical guideline development.
人们对将健康经济学纳入临床转化科学（尤其是营养干预措施）以实现社会效益的兴趣日益浓厚，这促使美国国立卫生研究院膳食补充剂办公室举办了一次会议，旨在解决营养干预措施经济分析方面的关键问题，加强健康经济学方法学家、研究人员、报销政策制定者和监管机构之间的沟通。讨论的问题包括科学现状，例如目前使用哪些健康经济学方法来判断疾病负担、干预措施或医疗保健政策，以及有哪些新的研究方法可用于解决知识和方法上的差距或障碍，或者需要哪些新的研究方法。研究应用包括联邦机构正在进行或计划进行的营养领域现有循证健康经济学研究活动。国际和美国的监管、政策和临床实践视角包括讨论研究结果如何帮助政府内的监管者和政策制定者做出营养政策决策，以及经济学如何影响临床指南的制定。
